ACHE and early-onset autosomal dominant Alzheimer disease: Despite being the most promising target in the pathology of Alzheimer’s disease, the AChE drugs approved by the FDA, namely, rivastigmine, donepezil, and galantamine, only provide symptomatic treatment.